| 经动脉灌注健择治疗中晚期胰腺癌临床疗效初步观察 |
| |
| 引用本文： | 刘德忠,李槐,曾辉英,李忱瑞,史仲华,周纯武.经动脉灌注健择治疗中晚期胰腺癌临床疗效初步观察[J].中国医学影像技术,2000,16(11):928-930. |
| |
| 作者姓名： | 刘德忠 李槐 曾辉英 李忱瑞 史仲华 周纯武 |
| |
| 作者单位： | 中国医学科学院中国协和医科大学肿瘤医院影像诊断科，北京 100021 |
| |
| 基金项目： | 本课题为国家“九五”攻关资助项目(96-907-03-05)。 |
| |
| 摘 要： | 目的 回顾性分析经动脉灌注健择（盐酸吉西他滨）治疗中晚期胰腺癌临床疗效。方法 １３例中晚期胰腺癌患者接受动脉灌注健择治疗。治疗后观察肿瘤改善情况及临床受益反应（ＣＢＲ）。结果 ＰＲ１例（７．７％），ＮＣ３例（２３％），ＳＤ３例（２３％），６例无法评价。Ｋａｐｌａｎ－Ｍｅｉｅｒ法计算６个月累积生存率为４６．８８％，频数分布法计算中位生存期为５．５个月，中位进展期为２．６９个月。临床受益率为３０．７６％与文献相比Ｐ〈０．００１）。结论 无论对于初治或化疗无效的病人，动脉灌注健择均显示出良好的临床受益反应；并能有效延长病人的生存时间。
|
| 关 键 词： | 胰腺癌 动脉灌注化疗 临床受益反应 |
| 文章编号： | 1003-3289(2000)11-0928-03 |
| 收稿时间： | 2000/7/26 0:00:00 |
| 修稿时间： | 2000年7月26日 |
Transarterial Infusion Chemotherapy of Gemcitabine for the Management of Advanced Pancreatic Carcinoma |
| |
| LIU De-zhong,LI Huai,ZENG Hui-ying,LI Chen-rui,SHI Zhong-hua and ZHOU Chun-wu.Transarterial Infusion Chemotherapy of Gemcitabine for the Management of Advanced Pancreatic Carcinoma[J].Chinese Journal of Medical Imaging Technology,2000,16(11):928-930. |
| |
| Authors: | LIU De-zhong LI Huai ZENG Hui-ying LI Chen-rui SHI Zhong-hua and ZHOU Chun-wu |
| |
| Institution: | Department of Diagnostic Radiology , Cancer Hospital of CAMS , Peking Medical College , Beijing 100021 , China;Department of Diagnostic Radiology , Cancer Hospital of CAMS , Peking Medical College , Beijing 100021 , China;Department of Diagnostic Radiology , Cancer Hospital of CAMS , Peking Medical College , Beijing 100021 , China;Department of Diagnostic Radiology , Cancer Hospital of CAMS , Peking Medical College , Beijing 100021 , China;Department of Diagnostic Radiology , Cancer Hospital of CAMS , Peking Medical College , Beijing 100021 , China;Department of Diagnostic Radiology , Cancer Hospital of CAMS , Peking Medical College , Beijing 100021 , China |
| |
| Abstract: | Purpose The effectiveness of transarterial infusion chemotherapy of gemcitabine for management of advanced pancreatic carcinoma was retrospectively analyzed. Methods Gemcitabine was administered to 13 patients with advanced pancreatic carcinoma via an interarterial catheter.Karnofsky performance score was (KPS)>50. Results Of 1 patient (7 7%) obtained partial response (PR), and 3 patients (23%) achieved no change of their disease.Probability for 6 month cumulative survival rate was 46 88%,median survival period was 5 5 months.No serious side effects were observed.Clinical benefit response (CBR) was 30 76%.The median time to progression was 2 69 months. Conclusion Transarterial infusion of gemcitabine appears well tolerated and promising CBR in patients with advanced pancreatic carcinoma. |
| |
| Keywords: | Pancreatic carcinoma Gemcitabine Transarterial chemotherapy Clinical benefit response |
| 本文献已被 维普 万方数据 等数据库收录！ |
| 点击此处可从《中国医学影像技术》浏览原始摘要信息 |
| 点击此处可从《中国医学影像技术》下载免费的PDF全文 |
|
